MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Amneal Pharmaceuticals DPO Ratio 2011-2026 | AMRX
Annual DPO Ratio Amneal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 19.3 | 21.2 | 21.1 | 35.2 | 29.5 | 44.3 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.3 | 19.3 | 28.4 |
Quarterly DPO Ratio Amneal Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.2 | 42.2 | 41.5 | 44.4 | 45.8 | 37.9 | 19 | 16.4 | 33.3 | 36.4 | - | - | - | 18.5 | - | - | - | 23.2 | - | - | - | 15 | - | - | - | 16.9 | - | 49.9 | 32.8 | 24.5 | - | 53.4 | 23.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53.4 | 15 | 31.8 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
193 | $ 0.77 | -4.12 % | $ 35.2 M |  Israel |
 |
Exelixis
EXEL
|
148 | $ 48.16 | 4.22 % | $ 13.1 B | USA |
 |
Fortress Biotech
FBIO
|
400 | $ 2.39 | -0.42 % | $ 66.7 M | USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.9 | 1.4 % | $ 271 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.4 | -0.71 % | $ 3.71 B | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.14 | - | $ 653 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
Gilead Sciences
GILD
|
45.3 | $ 131.33 | -2.04 % | $ 163 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 21.17 | 2.47 % | $ 2.69 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.57 | -2.48 % | $ 418 M | Britain |